Latham & Watkins Advises Ra Pharmaceuticals on US$2.1 Billion Acquisition by UCB

A bicoastal corporate team advised on the multi-billion dollar biopharmaceutical transaction.

October 10, 2019

UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) have announced their entry into a merger agreement pursuant to which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$48 in cash for each Ra Pharma share at closing, with a total transaction value of approximately US$2.1 billion. The Boards of Directors of both companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions. 

Latham & Watkins LLP represents Ra Pharmaceuticals Inc. in the transaction with a corporate deal team led by partners Scott Shean, Daniel Rees, and Peter Handrinos with associates Amro Suboh, Brian Umanoff, Stephanie Isaia, Madison Mapes, and Nicole McNeil. Advice was also provided on tax matters by partner Lisa Watts with associate Anne McGinnis; on benefits and compensation matters by partner Matthew Conway with associate Nikhil Kumar; on intellectual property matters by counsel David Kuiper; on antitrust matters by partner Joshua Holian; on finance matters by partner Wesley Holmes; and on regulatory matters by partner Elizabeth Richards.


Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.